-
Studies indicate that ghgh level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) could be detected in the blood [Review].
-
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
-
Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia
-
PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.
-
Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.
-
PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients.
-
ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors.
-
Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed
-
The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)
-
he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.
-
The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively.
-
The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients
-
this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians.
-
Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.
-
Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.
-
Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.
-
As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.
-
Older men who underwent no PSA testing or incomplete testing were significantly more likely to be diagnosed with high-risk prostate cancer than those who were previously screened. It is reasonable to consider screening in healthy older men likely to benefit from early detection and treatment.
-
end-of-radiation PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation.
-
the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH
